The National Healthcare Security Administration (NHSA) has published the National Reimbursement Drug List (2024) adjustment work plan, along with filing guidelines. The guidelines are largely consistent with the previous year’s National Reimbursement Drug List (NRDL) update.
Eligibility for consideration for NRDL inclusion is extended to all drugs that have received marketing approval or new indication approval after January 1, 2019. The list will particularly focus on removing conventional drugs that have not been supplied to designated medical institutions over the past three years and negotiation drugs that have not secured market supply. This year, there will be an emphasis on enhanced expert supervision and management. To provide stability for companies, the renewal and bidding rules for this year are fundamentally in line with those of previous years.
The deadline for adjustments remains December 31, as it was in the previous year. All negotiation-listed drugs on the NRDL for 8 consecutive years are eligible for conversion to regular listings. However, the only drugs that were newly added via negotiations in 2016 and thus meet the 8-year timeline are tenofovir disoproxil and gefitinib, both of which transitioned into regular management in 2017. Icotinib, which also transitioned into regular management in 2017 and negotiated a new indication in 2021, is expected to be joined by 9 newly added Western medicines from 2017, assuming no generic drugs are approved and no new indication approvals are granted.- Flcube.com
